CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 139 enrolled
Drug / intervention
CP-690,550 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00615199
NCT00615199Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study To Investigate The Safety And Efficacy Of CP-690,550 In Subjects With Moderate To Severe Crohn's Disease.

Pfizer·interventional·Posted Feb 14, 2008·Updated Jan 25, 2013

In Brief

A Phase 2 clinical trial evaluating CP-690,550 and Placebo for Crohn's Disease. Completed, enrolled 139 participants across 72 sites in 12 countries.

Detailed Summary

This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one of the dose levels to be tested will be more effective than placebo (inactive drug).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesBelgium, Czechia, France, Hungary, Italy, Netherlands, Poland, Slovakia, South Africa, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 14, 2008
Enrollment StartJan 1, 2008
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 18.4 years ago

Interventions

CP-690,550drug

administration via oral route twice daily

CP-690,550drug

administration via oral route twice daily

CP-690,550drug

administration via oral route twice daily

Placebodrug

administration via oral route twice daily